101.87
-0.04 (-0.03%)
| Penutupan Terdahulu | 101.90 |
| Buka | 101.81 |
| Jumlah Dagangan | 270,214 |
| Purata Dagangan (3B) | 5,293,265 |
| Modal Pasaran | 19,330,494,464 |
| Harga / Pendapatan (P/E Ke hadapan) | 185.19 |
| Harga / Jualan (P/S) | 6.23 |
| Harga / Buku (P/B) | 7.77 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Nov 2025 |
| Margin Keuntungan | -36.06% |
| Margin Operasi (TTM) | -11.53% |
| EPS Cair (TTM) | -5.53 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 10.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 105.93% |
| Nisbah Semasa (MRQ) | 2.73 |
| Aliran Tunai Operasi (OCF TTM) | 323.66 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 163.08 M |
| Pulangan Atas Aset (ROA TTM) | -1.83% |
| Pulangan Atas Ekuiti (ROE TTM) | -36.89% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menaik | Menaik |
| Diagnostics & Research (Global) | Menaik | Menaik | |
| Stok | Exact Sciences Corporation | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.38 |
|
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.92% |
| % Dimiliki oleh Institusi | 98.89% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 105.00 (Mizuho, 3.08%) | Pegang |
| 105.00 (Evercore ISI Group, 3.08%) | Pegang | |
| 105.00 (Stifel, 3.08%) | Pegang | |
| 105.00 (Canaccord Genuity, 3.08%) | Pegang | |
| 105.00 (Jefferies, 3.08%) | Pegang | |
| 105.00 (Wells Fargo, 3.08%) | Pegang | |
| 105.00 (Barclays, 3.08%) | Pegang | |
| Median | 105.00 (3.08%) | |
| Rendah | 75.00 (Benchmark, -26.37%) | Beli |
| 75.00 (Guggenheim, -26.37%) | Beli | |
| Purata | 94.46 (-7.27%) | |
| Jumlah | 6 Beli, 7 Pegang | |
| Harga Purata @ Panggilan | 86.51 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Mizuho | 20 Jan 2026 | 105.00 (3.08%) | Pegang | 102.35 |
| Evercore ISI Group | 05 Jan 2026 | 105.00 (3.08%) | Pegang | 101.61 |
| Stifel | 28 Nov 2025 | 105.00 (3.08%) | Pegang | 101.29 |
| 04 Nov 2025 | 80.00 (-21.46%) | Beli | 69.59 | |
| Canaccord Genuity | 25 Nov 2025 | 105.00 (3.08%) | Pegang | 101.13 |
| Jefferies | 24 Nov 2025 | 105.00 (3.08%) | Pegang | 101.01 |
| Barclays | 21 Nov 2025 | 105.00 (3.08%) | Pegang | 100.90 |
| 04 Nov 2025 | 77.00 (-24.41%) | Beli | 69.59 | |
| Wells Fargo | 21 Nov 2025 | 105.00 (3.08%) | Pegang | 100.90 |
| 05 Nov 2025 | 85.00 (-16.56%) | Beli | 69.63 | |
| Piper Sandler | 11 Nov 2025 | 80.00 (-21.46%) | Beli | 67.50 |
| BTIG | 04 Nov 2025 | 85.00 (-16.56%) | Beli | 69.59 |
| Baird | 04 Nov 2025 | 88.00 (-13.61%) | Beli | 69.59 |
| Benchmark | 04 Nov 2025 | 75.00 (-26.37%) | Beli | 69.59 |
| Guggenheim | 04 Nov 2025 | 75.00 (-26.37%) | Beli | 69.59 |
| TD Cowen | 04 Nov 2025 | 90.00 (-11.65%) | Beli | 69.59 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |